home / stock / lly / lly articles

LLY Articles, Eli Lilly and Company - From 03/08/24

Stock Information
Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com
Menu
LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan | Benzinga

Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift toward...
Eli Lilly's Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria, Impurities Detected | Benzinga

Eli Lilly And Co (NYSE:LLY) revealed on Thursday that it has identified bacteria and elevated impurity levels in products falsely claiming to ...

Insurance Coverage For Weight Loss Drugs - Cigna Unveils Efforts To Limit Health Plans/Employers Spending | Benzinga

Thursday, Evernorth Health Services, a subsidiary of Cigna Group (NYSE:CI) introduced a financial guarantee within its EncircleRx pr...

Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 | Benzinga

In a move outlined in his upcoming State of the Union address, President Joe Biden is pushing for an increase in the number of prescripti...
Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data | Benzinga

Thursday, Novo Nordisk A/S (NYSE:NVO) is holding its Capital Markets Day. Its executive management and other members of senior management...

Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk | Benzinga

Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound...

Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' | Benzinga

CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if underva...
Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets | Benzinga

BofA Securities says Eli Lilly and Company (NYSE:LLY) remains a top choice in Biopharma analysis, boasting a remarkable year-to-date...

$1000 Invested In This Stock 10 Years Ago Would Be Worth $13,000 Today | Benzinga

Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 10 years by 18.82% on an annualized basis producing an average annual return ...

Ozempic, Wegovy And Other Weight-Loss Drugs Won't Solve Global Obesity Crisis Affecting 1B People, WHO Warns | Benzinga

The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be res...
Previous 10 Next 10